On Apr. 20, 2020, Atossa Therapeutics announced that it had applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19 patients on mechanical ventilation. AT-H201 is a novel formulation of two pharmaceuticals previously approved by the FDA for other diseases.

The goal of the clinical trial, called the HOPE Study, was to demonstrate improved lung function and reduce the amount of time that COVID-19 patients are on ventilators.